Replies to post #215175 on Biotech Values

[DewDiligence]

SGMO—This tweet probably expresses the opinion of many biotech investors:

Have to say getting a bit tired of this $SGMO publicity stunt on making such a big deal out of this FIH trial.

Instead folks should pray nothing bad happens that may hurt the whole field of gene editing...

— Andy Biotech (@AndyBiotech) November 16, 2017